RMC-7977
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


RMC-7977
Description:
RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (Kd = 195 nM) and KRAS (G12V) (Kd = 292 μM) . It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRASG12C cancer models, and demonstrates good tolerability across various RAS cancer models[1][2][3].UNSPSC:
12352005Target:
AMPK; Apoptosis; ERK; PARP; Raf; Ras; Ribosomal S6 Kinase (RSK)Type:
Reference compoundRelated Pathways:
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; GPCR/G Protein; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/WntApplications:
Cancer-Kinase/proteaseField of Research:
CancerAssay Protocol:
https://www.medchemexpress.com/rmc-7977.htmlConcentration:
10mMPurity:
99.48Solubility:
DMSO : 100 mg/mL (ultrasonic)Smiles:
CO[C@H](C1=[C@@](C=C(N2CCN(C3CC3)CC2)C=N1)[C@@](N4CC)=C(C5=C4C=CC6=C5)CC(C)(C)COC([C@@H](N7)CCCN7C([C@@H](NC([C@@H]8[C@@H]9[C@H]8COC9)=O)CC%10=NC6=CS%10)=O)=O)CMolecular Formula:
C47H60N8O6SMolecular Weight:
865.11References & Citations:
[1]Singh M, et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Research Square; 2023.|[2]Popescu B, et al. RAS MULTI (ON) inhibitor RMC-7977 targets oncogenic RAS mutations and overcomes RAS/MAPK-mediated resistance to FLT3 inhibitors in AML models[J]. Blood, 2023, 142: 2793.|[3]Wasko UN, et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature. 2024 May;629 (8013) :927-936.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
No Development ReportedIsoform:
C-Raf; H-Ras; K-Ras; N-RasCAS Number:
[2765082-12-8]
